Lin, Huan-Ting
Takagi, Masatoshi
Kubara, Kenji
Yamazaki, Kazuto
Michikawa, Fumiko
Okumura, Takashi
Naruto, Takuya
Morio, Tomohiro
Miyazaki, Koji
Taniguchi, Hideki
Otsu, Makoto http://orcid.org/0000-0002-9769-0217
Funding for this research was provided by:
Japan Science and Technology Agency (JP16bm0609006, JP21bm0804004h0105, JP17ek0109233h0001)
Article History
Received: 25 January 2023
Accepted: 8 April 2024
First Online: 16 April 2024
Declarations
:
: All experiments were performed following the Declaration of Helsinki. BM aspirates from patients were used under adequately obtained informed consent. These studies were approved by the Ethics Committee of the Institute of Medical Science, University of Tokyo (Title: Drug discovery research and the investigation of disease pathology using patient-specific iPS cells, Approval reference #25–3-0701, Date: July 1, 2013; and Title: Development of innovative therapeutic strategies and the investigation of disease pathology using patient-specific iPS cells, Approval reference #30–8-A0522, Date: May 22, 2018), the Ethics Committee of Tokyo Medical and Dental University (Title: Research on childhood-onset hematological, immunological and genetic diseases using iPS cells, Approval reference #676, Date: Oct 27, 2009), and the Eisai Research Ethics Committee (Title: Genome and RNA analysis of human stem cells and their differentiated cells, Approval reference #2014-0238, Date: Aug 4, 2014; and Title: Pathophysiological elucidation and compound screening using iPS cells established from patients with RAS-related autoimmune lymphoproliferative syndrome-like disease (RALD), Approval reference #2014-0259, Date: Nov 19, 2014).
: Not applicable.
: RNAseq data are deposited in the NCBI GEO under the code GSE200600. Other data sets are available from the corresponding author upon request.
: The authors declare no competing interests.